19
Participants
Start Date
January 31, 2015
Primary Completion Date
December 31, 2015
Study Completion Date
March 31, 2016
Maraviroc 300 mg tablet (PO) and Maraviroc 1% gel (PR and PV)
"Tablets: daily 300 mg oral maraviroc, Selzentry®,(MVC) for 8 consecutive days Gel: daily rectally administered 1% MVC gel for 8 daily consecutive days Female Participants - will receive an additional third regimen of daily vaginally administered MVC 1% gel for 8 consecutive days.~Each treatment regimen will be followed by a washout period of 14 to 21 days.~Participants will also be randomized to a biopsy sampling schedule (i.e., D8, D9, or D10 sampling)."
Magee Women's Hospital of UPMC, Pittsburgh
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
National Institutes of Health (NIH)
NIH
International Partnership for Microbicides, Inc.
INDUSTRY